Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30719643 | 1.00 | LMNA (0.59) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL20579570 | 0.81 | LMNA (0.66) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL1786578 | 0.79 | ATM (0.73) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL6963334 | 0.78 | LMNA (0.58) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL29818828 | 0.78 | LMNA (0.58) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL30719637 | 0.78 | ATM (0.66) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL4722654 | 0.78 | ATM (0.66) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL23496915 | 0.77 | LMNA (0.53) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL14124174 | 0.77 | ROCK1 (0.56) | LMNATSHRATMNPSR1KDM4E | |
| SCHEMBL15897867 | 0.77 | LMNA (0.60) | LMNATSHRATMNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659025-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-03-08 | — | — | CN | disclosed |
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586191-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-111542515-B | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2023-12-05 | — | — | CN | disclosed |
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | UNIV COLORADO REGENTS (US) | 2023-04-27 | — | — | US | disclosed |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-06-17 | — | — | US | disclosed |
| CN-111542515-A | TOLL-like receptor 8(TLR8) specific antagonist and preparation method and application thereof | 科罗拉多州立大学董事会法人团体 | 2020-08-14 | — | — | CN | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066168-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | LMNA 3870/4885TSHR 500/4885ATM 3143/4885 |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | LMNA 1106/4885TSHR 1471/4885ATM 3548/4885 |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | LMNA 3732/4885TSHR 544/4885ATM 3168/4885 |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | TLR8, TLR3, TLR9 | LMNA 3732/4885TSHR 544/4885ATM 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.